Loading
Built MSK-IMPACT, the tumour sequencing test used on more than 100,000 patients and the first FDA-authorised hospital panel.
Michael Berger led the development of MSK-IMPACT, the hybrid-capture sequencing assay that profiles hundreds of cancer genes in every MSKCC patient and became the first laboratory-developed tumour panel authorised by the FDA. The 2017 Nature Medicine paper on 10,000 profiled patients showed how prospective clinical sequencing enables trial matching. He also co-developed MSK-ACCESS for ctDNA and OncoKB with Debyani Chakravarty.
Shares TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features and the tag genomics.
Shares Memorial Sloan Kettering Cancer Center, Comprehensive genomic profiling.
Shares Companion diagnostics, Comprehensive genomic profiling.
Shares FoundationOne CDx / Liquid CDx, Companion diagnostics, Comprehensive genomic profiling.
Shares TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features, Companion diagnostics and the tag genomics.
Shares Companion diagnostics, Comprehensive genomic profiling.